The product called Octaplex, currently under review by the Food and Drug Administration, would reverse the effects of warfarin — an oral drug that reduces blood clotting — in cases of major bleeding.

FRESNO COUNTY, Calif. (KFSN) -- Octapharma Plasma has closed all of its locations nationwide, including in Southeast Fresno and Clovis, citing network issues as the problem. The company pays people to ...

Paramus-based Octapharma USA is supporting a new investigator-initiated clinical trial led by Dr. George Sakoulas of Sharp Memorial Hospital in San Diego, Calif., focused on treating the most critical ...

PARAMUS, N.J. (December 2, 2020) - Clinical research presented by Octapharma USA at the 62nd American Society of Hematology (ASH) Annual Meeting and Exposition will highlight the investigational use ...

LACHEN, Switzerland--(BUSINESS WIRE)--Commenting on the Group’s results, Octapharma CEO and Chairman Wolfgang Marguerre said: “In 2018, we continued to drive growth in many of our products. I am ...

Octapharma Plasma says all of its more than 195 blood-plasma collection centers in 35 states nationwide — including three in Columbus — have been closed by what the company is blaming on IT "network ...

HOBOKEN, N.J. (May 13, 2010) - Octapharma USA today announced that wilate®, the first replacement therapy development specifically for von Willebrand Disease (VWD), is now available from the ...

SAN MATEO, Calif.--(BUSINESS WIRE)--Model N, Inc. (NYSE: MODN), the leader in cloud revenue management solutions, today announced that specialty manufacturer Octapharma USA, Inc. has selected the ...

PARAMUS, N.J., Aug. 20, 2024 /PRNewswire/ -- Octapharma USA has received U.S. Food and Drug Administration Emergency Use Authorization (EUA) for its proprietary octaplasLG Powder (blood group types A ...

LACHEN, Switzerland, June 10, 2024 /PRNewswire/ -- The most recent developments from Octapharma's Haematology portfolio will be presented at the 32 nd Congress of the International Society on ...